source
- Amgen ends partnership with TScan Therapeutics as Amylyx announces $350 million offeringAmgen announced it is terminating its collaboration with TScan Therapeutics, a Waltham, Massachusetts company focused on T‑cell therapies. The decision ends a partnership that had been aimed at de…
- AstraZeneca’s Tagrisso plus Orpathys improves survival in MET-mutated lung cancerA new combination therapy using AstraZeneca’s Tagrisso together with Hutchmed’s Orpathys has shown a survival benefit for patients with a specific form of non‑small cell lung cancer. The study focu…